Verici Dx Validates Gene Signature Test for Predicting Kidney Transplant Rejection
Verici Dx, a precision diagnostics company, has announced the publication of a clinical validation study for its Pre-Transplant Risk Assessment (PTRA) test. This test is designed to predict early acute rejection (EAR) in kidney transplant recipients. The study, published in Kidney360, demonstrates that the PTRA test outperforms conventional risk assessment tools, such as panel reactive antibodies, in predicting EAR within the first two months post-transplant. The test uses an RNA signature of 29 genes related to oxidative stress, endothelial injury, and immune pathways, focusing on the recipient's immune phenotype rather than donor characteristics. This approach allows for a more personalized management of immunosuppression, potentially reducing the risk of over-immunosuppression and its associated complications. 
